Medical Progress

Genetic Susceptibility to Venous Thrombosis

Uri Seligsohn, M.D., and Aharon Lubetsky, M.D.

The annual incidence of venous thrombosis, one of the leading causes of mortality and morbidity, increases from 1 per 100,000 during childhood to 1 per 100 in old age.1 In this article we will discuss conditions involving a genetic predisposition to venous thrombosis. The clinical relevance of this topic has increased with new evidence of the high prevalence of mutant genes that increase susceptibility to thrombosis.

Of the three mechanisms of thrombosis defined by Virchow in the 19th century — vessel-wall injury, stasis, and “changes in the composition of blood” (hypercoagulability) — the last two predominate in venous thrombosis. Hypercoagulability can be inherited or acquired (Table 1). The inherited type, which is also termed inherited thrombophilia, should be suspected when a patient has recurrent or life-threatening venous thromboembolism, has a family history of venous thrombosis, is younger than 45 years of age, or has no apparent acquired risk factors, or if the patient is a woman who has a history of multiple abortions, stillbirth, or both. Acquired and genetic causes frequently interact, which makes it difficult to decide which patients should be tested for inherited thrombophilia, what tests to perform and when to order them, whether the results of the tests will affect the duration of anticoagulant therapy, and whether to examine family members. This review addresses these and other topics related to hereditary thrombophilia.

HISTORICAL PERSPECTIVE

Antithrombin deficiency and dysfibrinogenemia, the first inherited thrombophilias to be described, were found in studies of families in which several members were affected by venous thrombosis.2,3 Later, heterozygous deficiencies of protein C4 and protein S5 were identified as causes of inherited thrombophilia. Initially, searches for inherited thrombophilias among patients with idiopathic venous thrombosis were disappointing, since only 5 to 20 percent of such patients had inherited thrombophilias.6 The situation changed remarkably in 1993, after the discovery of resistance to activated protein C. This condition is the most common cause of inherited thrombophilia.7 In most cases it results from the substitution of adenine for guanine at nucleotide 1691 of the factor V gene (G1691A), which causes the arginine in residue 506 of the factor V protein to be replaced by glutamine (Arg506Gln). The resulting protein is called factor V Leiden.8 In 1996, the substitution of adenine for guanine at nucleotide 20210 of the prothrombin gene (G20210A) was found to be another cause of thrombophilia.9 Homocystinuria, a rare type of thrombophilia, is manifested by both venous and arterial thrombosis.10 Familial venous thrombosis has also been associated with the occurrence of two or more inherited thrombophilias in the same person.11

MECHANISMS OF THROMBOSIS IN INHERITED THROMBOPHILIA

In most inherited thrombophilias, impaired neutralization of thrombin or a failure to control the generation of thrombin causes thrombosis (Fig. 1). In these cases, there is a malfunction in a system of natural anticoagulants that maintain the fluidity of the blood. One such anticoagulant is antithrombin, which, when bound to heparan sulfate on endothelial cells, neutralizes the procoagulants thrombin, factor Xa, factor IXa, and factor X. Protein C, another natural anticoagulant, controls the generation of thrombin.

---

Table 1. Inherited and Acquired Causes of Venous Thrombosis.

<table>
<thead>
<tr>
<th>Inherited</th>
<th>Common</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1691A mutation in the factor V gene (factor V Leiden)</td>
<td></td>
</tr>
<tr>
<td>G20210A mutation in the prothrombin (factor II) gene</td>
<td></td>
</tr>
<tr>
<td>Homozygous G677T mutation in the methylene tetrahydrofolate reductase gene</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Antithrombin deficiency</td>
<td></td>
</tr>
<tr>
<td>Protein C deficiency</td>
<td></td>
</tr>
<tr>
<td>Protein S deficiency</td>
<td></td>
</tr>
<tr>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Dysfibrinogenemia</td>
<td></td>
</tr>
<tr>
<td>Homozygous homocystinuria</td>
<td></td>
</tr>
<tr>
<td>Probably inherited</td>
<td></td>
</tr>
<tr>
<td>Increased levels of factor VIII, factor IX, factor XI, or fibrinogen*</td>
<td></td>
</tr>
<tr>
<td>Acquired</td>
<td></td>
</tr>
<tr>
<td>Surgery and trauma</td>
<td></td>
</tr>
<tr>
<td>Prolonged immobilization</td>
<td></td>
</tr>
<tr>
<td>Older age</td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td>Myeloproliferative disorders</td>
<td></td>
</tr>
<tr>
<td>Previous thrombosis</td>
<td></td>
</tr>
<tr>
<td>Pregnancy and the puerperium</td>
<td></td>
</tr>
<tr>
<td>Use of contraceptives or hormone-replacement therapy</td>
<td></td>
</tr>
<tr>
<td>Resistance to activated protein C that is not due to alterations in the factor V gene</td>
<td></td>
</tr>
<tr>
<td>Antiphospholipid antibodies</td>
<td></td>
</tr>
<tr>
<td>Mild-to-moderate hyperhomocysteinemia</td>
<td></td>
</tr>
</tbody>
</table>

*Levels of factor VIII and fibrinogen may also increase as part of the acute-phase response.

---

From the Institute of Thrombosis and Hemostasis and the National Hemophilia Center, Department of Hematology, Chaim Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv — both in Israel. Address reprint requests to Dr. Seligsohn at the Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel, or at zeligson@post.tau.ac.il.
The binding of thrombin to thrombomodulin on endothelial cells of small blood vessels neutralizes the procoagulant activities of thrombin and activates protein C. In large blood vessels, protein C binds to a specific receptor, and the binding augments the activation of protein C by thrombin. Activated protein C inactivates factors Va and VIIIa in the presence of free protein S and phospholipids, thereby inhibiting the generation of thrombin. Free protein S itself has anticoagulant effects: it inhibits the prothrombinase complex (factor Xa, factor Va, and phospholipid), which converts prothrombin to thrombin, and the tenase complex (factor IXa, factor VIIIa, and phospholipid), which converts factor X to factor Xa. A decrease in antithrombin activity impairs the neutralization of thrombin, and the reduced activity of protein C or protein S diminishes the control of thrombin generation. Both these mechanisms increase susceptibility to venous thrombosis (Fig. 1).

The control of thrombin generation is also compromised by mutations in the gene for factor V or prothrombin. The Arg506Gln substitution in factor V Leiden involves the first of three sites on factor Va that are cleaved by activated protein C. This mutation slows down the proteolytic inactivation of factor Va, which in turn leads to the augmented generation of thrombin. Moreover, the mutant factor V has diminished cofactor activity in the inactivation of factor VIIIa by activated protein C. Both these abnormalities in factor V cause the in vitro phenomenon of resistance to activated protein C, resulting in the failure of activated protein C to prolong the activated partial-thromboplastin time. For unknown reasons, the G20210A mutation in the 3’ untranslated region...
of the prothrombin gene is associated with an increased level of plasma prothrombin, an effect that promotes the generation of thrombin and impairs the inactivation of factor Va by activated protein C.14,15 The mechanisms by which increased levels of factor VIII, factor IX, factor XI, fibrinogen, and homocysteine enhance venous thrombosis are unknown.

**EPIDEMIOLOGIC AND GENETIC FEATURES OF INHERITED THROMBOPHILIA**

The frequency of the major inherited thrombophilias varies substantially within healthy populations and among patients with venous thrombosis. Factor V Leiden and the G20210A mutation in the prothrombin gene are common among healthy whites but are extremely rare among Asians and Africans. Founder effects have been demonstrated for both mutations, suggesting that they occurred after the separation of non-Africans from Africans and after the divergence of whites and Asians.16,17 The frequency of all inherited thrombophilias is significantly higher in unselected consecutive patients with venous thrombosis than in healthy subjects.18-47 This difference is striking in selected patients with venous thrombosis who are also likely on clinical grounds to have an inherited thrombophilia (Table 2).

Since factor V Leiden and the G20210A mutation in the prothrombin gene are relatively common, their coinheritance with other thrombophilias is not rare. Four studies that together enrolled 677 members of families with deficiencies of protein C, protein S, or antithrombin demonstrated that the prevalence of venous thrombosis was 13 to 25 percent among subjects with only factor V Leiden, 19 to 57 percent among subjects with only one of the three deficiencies, and 73 to 92 percent among subjects who co-inherited one of the deficiencies and factor V Leiden.48-51 Similar interactions were observed between factor V Leiden and the G20210A mutation in the prothrombin gene.52 Hyperhomocysteinemia also interacts with factor V Leiden and the G20210A mutation in the prothrombin gene; the combination of hyperhomocysteinemia with either factor significantly increases the risk of venous thrombosis.53,54

Numerous mutations have been described in patients with a deficiency of protein C, protein S, or antithrombin (Table 3). Type I defects (low activity and low antigen level) predominate in patients with a deficiency of protein C or S, whereas both type I and type II (low activity and normal antigen level) defects are common in patients with antithrombin deficiency. In these three disorders, heterozygotes are susceptible to venous thrombosis, except for those with type II antithrombin deficiency involving the heparin-binding site.55 Homozygous antithrombin deficiency is probably incompatible with life unless it is a type II defect involving the heparin-binding site, in which the susceptibility to venous thrombosis is indistinguishable from that of persons with hetero-

![Table 2: Frequency of Inherited Thrombophilias among Healthy Subjects and Unselected and Selected Patients with Venous Thrombosis.](image-url)

*Nonconsecutive patients who met the following criteria were selected: an age of less than 50 years, a family history of venous thrombosis, a history of recurrent events, and the absence of acquired risk factors except for pregnancy or the use of oral contraceptives.

†All subjects were white.

‡All subjects were African or Asian (African Americans were excluded).
zygous antithrombin deficiency. Persons with a homozygous deficiency of protein C or protein S are exceedingly rare and present soon after birth with purpura fulminans or massive venous thrombosis. Persons who are homozygous for factor V Leiden or the G20210A mutation in the prothrombin gene are more common and have a predisposition to venous thrombosis. The predisposition is greater in heterozygotes for factor V Leiden than in homozygotes.

Factor V Leiden is not the only cause of resistance to activated protein C. The HR$_2$ haplotype, a unique and relatively common haplotype of the factor V gene, causes resistance to activated protein C and increases the risk of venous thrombosis when co-inherited with factor V Leiden. There is also a rare mutation in the second of the three sites in factor Va that activated protein C cleaves (Arg306Thr). Additional causes of resistance to activated protein C, probably genetic but as yet unidentified, also increase the risk of venous thrombosis.

Hyperhomocysteinemia, a risk factor for venous thrombosis, can be caused by genetic disorders affecting the trans-sulfuration or remethylation pathways of homocysteine metabolism, or by folic acid deficiency, vitamin B$_12$ deficiency, vitamin B$_6$ deficiency, renal failure, hypothyroidism, increasing age, and smoking. A rare example of excessive hyperhomocysteinemia is homozygous homocystinuria due to cystathionine-β-synthase deficiency; 50 percent of affected patients present with venous or arterial thrombosis by the age of 29 years. Homozygosity for the C677T mutation in the methylenetetrahydrofolate reductase gene is a cause of mild hyperhomocysteinemia in 5 to 15 percent of white and East Asian populations, but its relation to venous thrombosis is controversial.

Elevated levels of factor VIII, factor IX, factor XI, and factor XII are common findings in patients with venous thrombosis. The mechanism of these increases is unknown, but they may be due to activation of these plasma proteins caused by activated clotting factors. Activated factor VIII, such as that produced by factor XI and factor XII, may be a cause of thrombosis in patients with factor VIII deficiency. The factor VIII level may be increased in patients with venous thrombosis due to the presence of lupus anticoagulant or anticardiolipin antibodies. The presence of lupus anticoagulant is characterized by a prolonged activated partial thromboplastin time and a positive test for lupus anticoagulant. The presence of anticardiolipin antibodies is characterized by a positive test for anticardiolipin antibodies and a negative test for lupus anticoagulant.

Table 3. Diagnostic Tests for Thrombophilies.

<table>
<thead>
<tr>
<th>Test*</th>
<th>Genetic Basis for Test Result</th>
<th>Acquired Conditions or States That Can Account for Test Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>High priority</td>
<td>Increased resistance to activated protein C</td>
<td>Factor V Leiden, HR$_2$ haplotype</td>
</tr>
<tr>
<td></td>
<td>Heterozygosity or homozygosity for factor V Leiden</td>
<td>G1691A in exon 10</td>
</tr>
<tr>
<td></td>
<td>Heterozygosity or homozygosity for G20210A prothrombin gene mutation</td>
<td>G20210A in the untranslated region of the gene</td>
</tr>
<tr>
<td></td>
<td>Increased level of homocysteine</td>
<td>Mutations in the genes for cystathionine β-synthase or methyltetrahydrofolate reductase</td>
</tr>
<tr>
<td></td>
<td>Increased level of factor VIII</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>Presence of lupus anticoagulant</td>
<td>—</td>
</tr>
<tr>
<td>Intermediate priority</td>
<td>Decreased protein C activity</td>
<td>161 Different mutations†</td>
</tr>
<tr>
<td></td>
<td>Decreased level of free protein S antigen</td>
<td>131 Different mutations‡</td>
</tr>
<tr>
<td></td>
<td>Decreased antithrombin activity</td>
<td>127 Different mutations‡</td>
</tr>
<tr>
<td></td>
<td>Increased titer of anticardiolipin antibodies</td>
<td>—</td>
</tr>
<tr>
<td>Low priority</td>
<td>Dysfibrinogenemia (normal or low fibrinogen level and prolonged thrombin time)</td>
<td>20 Different mutations‡</td>
</tr>
<tr>
<td></td>
<td>Increased level of fibrinogen</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>Increased factor XI activity</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>Homozygosity for C677T mutation in methylenetetrahydrofolate reductase gene</td>
<td>C677T in exon 4</td>
</tr>
</tbody>
</table>

*Priority for testing is defined in the chart outlined in Figure 2.
†A compendium of the point mutations that have been described is available at http://www.uwcm.ac.uk/uwcm/mg/hgmd0.html.
‡A compendium of the point mutations that have been described is available at http://www.geht.org/pages/database_ang.html.
or fibrinogen increase the risk of venous thrombosis, but so far no genetic alterations have been demonstrated in any of these conditions.  

**CLINICAL FEATURES OF INHERITED THROMBOPHILIA**

Persons with a heterozygous deficiency of protein C, protein S, or antithrombin and those who are heterozygous or homozygous for factor V Leiden or the G20210A mutation in the prothrombin gene typically present with deep-vein thrombosis of the legs, pulmonary embolism, or both. Less common manifestations are superficial venous thrombosis and thromboses in the cerebral, visceral, and axillary veins. In more than half the cases, venous thrombosis is provoked by surgery, immobilization, advanced age, pregnancy, or the use of oral contraceptives or hormone-replacement therapy.

In most patients with inherited thrombophilia, the first thrombotic event occurs before the age of 45 years. The first event is even earlier in patients who have more than one inherited thrombophilia or who are homozygous for factor V Leiden or the G20210A mutation in the prothrombin gene. Asymptomatic heterozygotes who are relatives of index patients with inherited thrombophilia have a significant risk of venous thrombosis. The highest risk, 0.87 to 1.6 percent per year, was observed in persons who were heterozygous for antithrombin deficiency, and the lowest, 0.25 to 0.45 percent per year, was seen in persons who were heterozygous for factor V Leiden. Persons who are heterozygous for the G20210A mutation in the prothrombin gene, protein C deficiency, or protein S deficiency have an annual incidence of venous thrombosis of 0.55 percent, 0.43 to 0.72 percent, and 0.5 to 1.65 percent, respectively.

**RECURRENT VENOUS THROMBOSIS**

All patients with venous thrombosis, whether or not they have a known inherited thrombophilia, are prone to recurrent thromboses for many years after the first incident. Recurrence is fatal in approximately 5 percent of patients, and in one third of patients, it is associated with the post-thrombotic syndrome. Recurrent venous thrombosis requires prolonged therapy with anticoagulants, which itself carries a significant risk of major hemorrhage. Recurrence is more common in men, the elderly, patients who are immobilized, patients with cancer, patients who have had an unprovoked thrombotic event, and patients who have already had a recurrent thrombosis. Increased levels of factor VIII and homocysteine also increase the risk of recurrence.  

The effect of inherited thrombophilias on recurrent venous thrombosis has been assessed mainly in retrospective studies. Recurrent venous thrombosis is more common in patients with a deficiency of antithrombin, protein C, or protein S; in those with more than one inherited thrombophilia; and in those who are homozygous for factor V Leiden. Whether persons who are heterozygous for factor V Leiden or the G20210A mutation in the prothrombin gene have increased rates of recurrence of venous thrombosis is controversial.

**INHERITED THROMBOPHILIAS DURING PREGNANCY AND THE Puerperium**

The predominant sites of thrombosis during pregnancy are the iliofemoral veins and the veins of the left leg. The risk of venous thrombosis in women with a deficiency of antithrombin, protein C, or protein S is substantially increased during pregnancy and the puerperium. A review of uncontrolled retrospective studies found that venous thrombosis occurred during pregnancy and the puerperium in up to 60 percent of women with an antithrombin deficiency and in up to 20 percent of women with a deficiency of either protein C or protein S. A case–control study showed that among 129 asymptomatic female relatives of patients with a deficiency of antithrombin, protein C, or protein S, those who also had a deficiency of one of these proteins had a risk of venous thrombosis during pregnancy and the puerperium that was eight times as high as the risk in those without a deficiency. An increased risk of venous thrombosis during pregnancy is also associated with factor V Leiden (odds ratio, 16.3; 95 percent confidence interval, 4.8 to 54.9) and the G20210A mutation in the prothrombin gene (odds ratio, 10.2; 95 percent confidence interval, 4.0 to 25.9). Coinheritance of factor V Leiden and the G20210A mutation in the prothrombin gene further increases the risk (estimated odds ratio, 107).

Inherited thrombophilias also increase the risk of fetal loss. In a large cohort of women with a deficiency of antithrombin, protein C, or protein S or factor V Leiden, the odds ratios for fetal loss after 28 weeks of gestation (stillbirth) were 5.2, 2.3, 3.3, and 2.0, respectively; the odds ratio was 14.3 for women with more than one type of inherited thrombophilia. Another study found that the risk of late fetal loss (after 20 weeks of gestation) was tripled in carriers of the G20210A mutation in the prothrombin gene or factor V Leiden. An increased relative risk of early fetal loss (at less than 25 weeks of gestation) was also observed in women with a deficiency of protein C, protein S, or antithrombin, and in carriers of factor V Leiden. In a more general case–control study, 52 percent of pregnant women with fetal growth retardation, preeclampsia, abruptio placenta, or stillbirth were heterozygous for factor V Leiden or the G20210A mutation in the prothrombin gene or homozygous for the C677T mutation in the gene for methylenetetrahydrofolate reductase, as compared with 17 percent of controls. These data provide a rationale for screening women who intend to...
become pregnant for inherited thrombophilias if they have a personal or family history of venous thrombosis or if they have three unexplained miscarriages, abruptio placentae, stillbirth, recurrent fetal growth retardation, or possibly preeclampsia.

**ORAL CONTRACEPTIVES AND HORMONE-REPLACEMENT THERAPY**

The use of oral contraceptives significantly increases the risk of venous thrombosis in a woman with an inherited thrombophilia. In a study of women using oral contraceptives, the risk was increased by a factor of 3.8 in normal women and by a factor of 34.7 in women who were heterozygous for factor V Leiden. Increased risks were also conferred by heterozygosity for the G20210A mutation in the prothrombin gene, a deficiency of protein C, or a deficiency of protein S. Among women with antithrombin deficiency, the incidence of venous thrombosis was 27 percent per year in users of contraceptives, as compared with 3.4 percent per year in nonusers. Among women with factor V Leiden, the risk of venous thrombosis with the use of third-generation contraceptives is twice that with the use of second-generation contraceptives, probably because the third-generation contraceptives result in a more pronounced resistance to activated protein C.

For these reasons, women with inherited thrombophilias should avoid using oral contraceptives, particularly when they have a personal or family history of venous thrombosis. Screening of healthy women for thrombophilias, however, is not recommended, since it would deny contraceptives to about 5 to 10 percent of white women with factor V Leiden or the G20210A mutation in the prothrombin gene, while preventing very few fatal venous thromboembolisms. Screening should be confined to women with a personal or family history of thrombosis.

Hormone-replacement therapy in healthy women increases the risk of venous thrombosis by a factor of two to four, but the increased risk probably disappears after one year of treatment. A recent study found that the risk was significantly increased in women with antithrombin deficiency, resistance to activated protein C, or increased levels of factor IX. Until more data are available, it is advisable to search for inherited thrombophilias only in women with a personal or family history of venous thrombosis and to avoid hormone-replacement therapy in affected women unless it is strongly indicated.

**DIAGNOSIS OF INHERITED THROMBOPHILIA**

With the identification of factor V Leiden and the G20210A mutation in the prothrombin gene, the proportion of patients with venous thrombosis in whom a diagnosis of inherited thrombophilia can be established has increased. In unselected patients, the rate has increased from approximately 10 percent to approximately 30 percent, and in patients with a clinical likelihood of having an inherited thrombophilia, it has increased from approximately 17 percent to approximately 70 percent. What is the most economical way of testing for an inherited thrombophilia? Decisions regarding laboratory tests in a given patient can be made according to a set of priorities (Table 3) and individualized after the likelihood of inherited thrombophilia is assessed, taking into account that in a few cases the diagnosis will be missed (Fig. 2). The inclusion of all six high-priority tests in the evaluation (Table 3) should provide the highest diagnostic yield, because the six conditions being tested for are relatively frequent. Measurement of resistance to activated protein C in plasma diluted with factor V-deficient plasma is not only highly sensitive and specific for factor V Leiden but is also accurate in patients whose plasma contains lupus anticoagulant or increased levels of factor VIII and in patients taking oral anticoagulants. It is also advisable to confirm the diagnosis of factor V Leiden by a genetic test, because this information can be used in deciding whether family members should be examined. In patients with stroke or with antibodies to activated protein C, resistance to activated protein C can be delineated only by testing undiluted plasma (Table 3).

Tests of intermediate priority (Table 3) yield positive results less frequently, and low-priority tests only very rarely diagnose an inherited thrombophilia (e.g., dysfibrinogenemia). The association between venous thrombosis and the C677T mutation in the gene for methylenetetrahydrofolate reductase or increased levels of fibrinogen, factor IX, or factor XI has not been definitively established.

The optimal time for performing tests in most patients is six months after the thrombotic event, when a decision should be made about continuing anticoagulant therapy (Fig. 2). The results of examinations performed earlier can be misleading, because thrombosis itself can cause low antithrombin levels and elevated levels of factor VIII. At six months, all high-priority tests and a test for antithrombin activity should be performed in patients who are most likely to have an inherited thrombophilia. These patients should then be switched to treatment with low-molecular-weight heparin for two weeks and subsequently tested for protein C activity and the level of free protein S antigen. If none of these test results are abnormal in a patient with a family history of venous thrombosis or a recurrent thrombosis, it is reasonable to perform low-priority tests (Table 3). In our algorithm (Fig. 2), patients likely to have thrombophilia undergo only high-priority tests, but if factor V Leiden, the G20210A mutation in the prothrombin gene, or a lupus anticoagulant is detected, intermediate-priority tests should also be performed. Patients with the least likelihood of having thrombophilia are not tested...
Figure 2. Approach to the Diagnosis and Treatment of Thrombophilia in Patients with Venous Thrombosis.

Panel A shows the clinical evaluation of the likelihood of thrombophilia, initial anticoagulant therapy, and the performance of tests.

Panel B shows the criteria for continuing therapy and for prophylaxis.

Thrombophilia likely in a patient who meets one of the following criteria:
- First unprovoked event
- Event provoked by pregnancy or the puerperium or the use of oral contraceptives or hormone-replacement therapy
- Proximal-vein thrombosis, pulmonary embolism, or both provoked by surgery, trauma, or immobilization
- Age of more than 45 years

Thrombophilia highly likely in a patient with an unprovoked thrombotic event who meets one of the following criteria:
- Age of less than 45 years
- Recurrent event
- Family history of venous thrombosis
- Cerebral- or visceral-vein thrombosis
- Stillbirth
- Three or more unexplained spontaneous abortions

Thrombophilia unlikely:
- Distal-vein thrombosis provoked by surgery, trauma, or immobilization

Therapy should be stopped unless cancer is still active, immobilization continues, or severe venous insufficiency is present. Initiation of prophylaxis (use of unfractionated or low-molecular-weight heparin during high-risk situations, such as surgery, trauma, immobilization, or air travel for more than 4 hours; avoidance of oral contraceptives and hormone-replacement therapy; maintenance of normal homocysteine levels; and maintenance of normal weight)

Therapy should be stopped if the patient meets any of the following criteria:
- No thrombophilia
- Heterozygosity for factor V Leiden or G20210A mutation in the prothrombin gene
- High risk of bleeding (as indicated by the presence of one or more of the following: age of more than 70 years, history of gastrointestinal bleeding, history of stroke, renal insufficiency, poorly controlled anticoagulation, and use of antiplatelet drugs)

Therapy should be continued indefinitely in patients who meet any of the following criteria:
- Life-threatening event
- Cerebral- or visceral-vein thrombosis
- Recurrent event
- Antithrombin deficiency
- Homozygosity for factor V Leiden
- Combined thrombophilias
- Presence of antiphospholipid antibodies

Therapy should be continued for an additional 6 to 18 months in patients who meet any of the following criteria:
- Active cancer
- Continued immobilization
- Venous insufficiency
- Deficiency of protein C or S
- Elevated factor VIII level
- Standard risk of bleeding

Therapy should be stopped if the patient meets any of the following criteria:
- No thrombophilia
- Heterozygosity for factor V Leiden or G20210A mutation in the prothrombin gene
- High risk of bleeding (as indicated by the presence of one or more of the following: age of more than 70 years, history of gastrointestinal bleeding, history of stroke, renal insufficiency, poorly controlled anticoagulation, and use of antiplatelet drugs)

Initiation of prophylaxis (use of unfractionated or low-molecular-weight heparin during high-risk situations, such as surgery, trauma, immobilization, or air travel for more than 4 hours; avoidance of oral contraceptives and hormone-replacement therapy; maintenance of normal homocysteine levels; and maintenance of normal weight)
at all; the anticipated recurrence of venous thrombosis in them is low (1.5 percent per year) and does not outweigh the risk of bleeding due to the prolongation of anticoagulant therapy.\textsuperscript{100}

Before establishing the diagnosis of an inherited thrombophilia, it is essential to rule out acquired conditions that may produce similar results (Table 3); it is also advisable to repeat nongenotypic tests with abnormal results. Detection of the same abnormality in first-degree relatives of the patient provides evidence of a possible genetic defect.

First-degree relatives of patients with one or more abnormal test results should be examined to determine whether they should receive primary prophylaxis. A reasonable approach is to test for only the abnormal factor or factors found in the index patient when there is no family history of venous thrombosis and to perform all tests of high and intermediate priority when there is a family history.

**THERAPY AND PROPHYLAXIS**

Patients with a known or unknown inherited thrombophilia who present with venous thromboembolism should be treated with a standard regimen of heparin overlapped with warfarin until an international normalized ratio (INR) of 2.0 to 3.0 is obtained on two consecutive days. This regimen is sufficient for the prevention of skin necrosis, which may occur during the initiation of warfarin therapy in patients with a deficiency of protein C. The chief goals of therapy are to prevent recurrent venous thromboembolism, which is fatal in 5 percent of cases.\textsuperscript{71} Recurrent thromboses also increase the risk of venous insufficiency\textsuperscript{2} and impose a need for indefinite anticoagulant therapy, which carries a significant risk of bleeding. Warfarin therapy reduces the risk of recurrence by 90 to 95 percent, but the annual risk of fatal hemorrhage is 0.25 percent.\textsuperscript{101} Consequently, the benefits and hazards associated with increasing the duration of therapy should be carefully evaluated and discussed with each patient, with consideration of the patient’s preference and clinical and laboratory risk factors that increase susceptibility to recurrent venous thrombosis or hemorrhage. Comprehensive, evidence-based guidelines for therapy cannot yet be formulated, but the substantial information reviewed in this article and our own experience lead us to an algorithm that applies to all patients with established venous thrombosis (Fig. 2).

During the initiation of therapy, patients are classified according to their likelihood of having thrombophilia. Patients with the lowest likelihood are treated for three months, and no tests for thrombophilia are performed. All other patients are treated with warfarin for six months, after which they are examined for the presence of thrombophilia and assessed for the risks of recurrence and hemorrhage. On the basis of this assessment, treatment is discontinued, continued for 6 to 18 more months, or continued indefinitely.

In patients with hyperhomocysteinemia, we recommend indefinite treatment with folic acid, supplemented by vitamins B\textsubscript{6} and B\textsubscript{12}; if normal levels of homocysteine are not achieved with folic acid alone. Annual testing of serum vitamin B\textsubscript{12} levels is advisable to avoid potential deleterious effects of folic acid in patients with vitamin B\textsubscript{12} deficiency.

All patients with venous thrombosis of the legs should wear fitted compression stockings for at least two years; this measure reduces the incidence of the post-thrombotic syndrome by 50 percent.\textsuperscript{102} Other prophylactic measures for patients who discontinue therapy are given in Figure 2. Women with an inherited thrombophilia who have had venous thrombosis, stillbirth, or three unexplained spontaneous abortions should be treated throughout pregnancy and for six weeks post partum with low-molecular-weight heparin. Patients with antithrombin deficiency probably require a more intensive regimen.\textsuperscript{103}

First-degree relatives of index patients who are asymptomatic but who are affected by a thrombophilia should be advised of the risk of venous thrombosis. Primary prophylaxis in these persons includes the administration of low-molecular-weight heparin in high-risk conditions, such as during surgery, trauma, immobilization, and the six-week postpartum period; maintenance of normal weight and homocysteine levels; and avoidance of contraceptives and hormone-replacement therapy, with the patient’s preference taken into account. Women with antithrombin deficiency, combined thrombophilia, or homozygosity for factor V Leiden or the G20210A mutation in the prothrombin gene should be treated throughout pregnancy and for six weeks post partum with low-molecular-weight heparin.

**REFERENCES**

10. Madd SH, Skowby F, Levy HJ, et al. The natural history of homocys-


